One-Time cell therapy tested for Tough-to-Treat blood cancer
NCT ID NCT02601313
Summary
This study tested an experimental one-time treatment called KTE-X19 for adults with mantle cell lymphoma, a type of blood cancer, that had returned or stopped responding to other therapies. The treatment involves collecting a patient's own immune cells, modifying them in a lab to better target the cancer, and then infusing them back. The main goal was to see how well this approach could shrink or eliminate the cancer in 105 participants who had already tried several other treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Academisch Medisch Centrum
Amsterdam, Netherlands
-
Banner MD Anderson
Gilbert, Arizona, 85234, United States
-
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
Baylor Charles A. Sammons Cancer Center
Dallas, Texas, 75246, United States
-
Centre Hospitalier Universitaire (CHU)
Bordeaux, France
-
City of Hope
Duarte, California, 91010, United States
-
Cleveland Clinic Foundation
Cleveland, Ohio, 44195, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
Erasmus Medical Center
Rotterdam, Netherlands
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
H Lee Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
Hopital Haut-Leveque
Pessac, 44035, France
-
Hospital Saint Louis
Paris, 75010, France
-
Loyola University Chicago
Maywood, Illinois, 60153, United States
-
Ohio State University
Columbus, Ohio, 43210, United States
-
Robert W. Franz Cancer Research Center
Portland, Oregon, 97213, United States
-
Sarah Cannon
Denver, Colorado, 80218, United States
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
-
Stanford University
Stanford, California, 94305, United States
-
Swedish Cancer Institute
Seattle, Washington, 98104, United States
-
Universitaetsklinikum Wuerzburg
Würzburg, 97080, Germany
-
University California Los Angeles (UCLA)
Santa Monica, California, 90404, United States
-
University Medical Center Groningen
Groningen, Netherlands
-
University of Chicago
Chicago, Illinois, 60637, United States
-
University of Miami
Miami, Florida, 33136, United States
-
University of Rochester Medical Center
Rochester, New York, 14642, United States
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Universitätsklinik Dresden
Dresden, 01307, Germany
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37232, United States
-
Winship Cancer Institute of Emory University
Atlanta, Georgia, 30322, United States
Conditions
Explore the condition pages connected to this study.